Skip to main content
SpringerLink
Log in

Therapeutic Aspects of Platelet Pharmacology

  • Chapter
Book cover Platelets and Their Factors

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 126))

Abstract

Pharmacological, angiographic, and biochemical studies indicate that platelets may play a key role in the initiation and evolution of atherosclerosis. They are also key to occlusive complication of the atherosclerotic plaque manifest clinically as unstable angina or myocardial infarction (Lewis et al. 1983; Cairns et al. 1985; Ambrose et al. 1986; Sherman et al. 1986; Fitzgerald et al. 1986; Theroux et al. 1987).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V (1986) Angiographic evolution of coronary artery morpholgy in unstable angina. J Am Coll Cardiol 7:474–478

    Article  Google Scholar 

  • Antiplatelet Trialists’ Collaboration (1988) Secondary prevention of vascular disease by prolonged antiplatelet treatment. Brit Med J 296:320–331

    Article  Google Scholar 

  • Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Brit Med J 308:81–106

    Google Scholar 

  • Bellavance A, for the Ticlopidine Aspirin Stroke Study Group (1993) Efficacy of ticlopidine and aspirin for the prevention of reversible cerebrovascular ischemic events: the Ticlopidine Aspirin Stroke Study. Stroke 24:1452–1457

    Article  Google Scholar 

  • Bertele’ V, Cerletti C, Schippati A, di Minno G, de Gaetano G (1981) Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet i:1057–1058

    Article  Google Scholar 

  • Bertele’ V, de Gaetano G (1982) Potentiation by dazoxiben, a thromboxane synthetasse inhibitor, of platelet aggregation inhibition activity of a thromboxane receptor antagonist and of prostacyclin. Eur J Pharmacol 85:331–333

    Article  Google Scholar 

  • Bourassa MG, Schwartz L, Lesperance J, Eastwood C, Kazim F (1990) Prevention of acute complications after percutaneous transluminal coronary angioplasty. Thrombosis Res Suppl 12:51–58

    Article  CAS  Google Scholar 

  • Braden GA, Knapp HR, FitzGerald GA (1991) Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation 84:679–685

    PubMed  CAS  Google Scholar 

  • Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealey BJ, Tanser PH (1985) Aspirin, Sufinpyrazone, or both in unstable angina. Results of a Canadian Multicenter Trial. N Engl J Med 313:1369–1375

    Article  PubMed  CAS  Google Scholar 

  • Cannon CP, Novotny WF, McCabe CH, Tischler MD, Borzac S, Henry TD, Feldman R, Hamilton S, Rothman JM, Braunwald E, and the TIMI Investigators (1996) Evaluation of the oral glycoprotein IIb/IIIa antagonist Ro 48–3657 in patients post acute coronary syndromes: primary results of the TIMI 12 trial. Circulation 94:3231 A

    Google Scholar 

  • CAPRIE Steering Committee (1996) A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339

    Article  Google Scholar 

  • Charo JF, Bekeart LS, Phillips DR (1987) Platelet glycoprotein IIb/IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. J Biol Chem 262:9935–9938

    PubMed  CAS  Google Scholar 

  • Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US (1994) Inhibition of neointimal hyperplasia by blocking α v β 3 integrin with a small peptide antagonist Gpen GRGDSPCA. J Vase Surg 19:125–134

    CAS  Google Scholar 

  • Clarke RJ, Mayo G, Price P, FitzGerald GA (1991) Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325:1137–1141

    Article  PubMed  CAS  Google Scholar 

  • Coller BS, Peerschke EI, Scudder LE, Sullivan CA (1983) A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thromboasthenic-like state in normal platelets and binds to glycoprotein IIb and/ or IIIa. J Clin Invest 72:325–338

    Article  PubMed  CAS  Google Scholar 

  • De Witt DL, Smith WL (1988) Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85:1412–1416 (Erratum: Proc Natl Acad Sci USA 85:5056, 1988)

    Google Scholar 

  • Di Minno G, Cerbone AM, Mattioli PM, Turco S, Iovine C, Mancini M (1985) Functionally thromboasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 75:328–338

    Article  PubMed  Google Scholar 

  • Diener H, Cuhla L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurolog Sci 143:1–13

    Article  CAS  Google Scholar 

  • Doolittle RF, Watt KWK, Cottrell BA et al. (1979) The aminoacid sequence of the α chain of human fibrinogen. Nature 280:464–468

    Article  PubMed  CAS  Google Scholar 

  • D’Souza SE, Ginsberg MH, Plow EF (1991) Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci 16:246–250

    Article  PubMed  Google Scholar 

  • Dunn FW, Soria J, Soria C, Thomaidis A, Lee H, Caen JP (1984) In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen on platelets. Agents Actions 15:97–103

    Article  CAS  Google Scholar 

  • Ferguson JJ, McDonough TJ, Worley SJ et al. (1996) Clinical outcome of “high-risk” vs “elective” patients undergoing percutaneous coronary intervention: results from IMPACT II. J Am Coll Cardiol 27:180A

    Google Scholar 

  • Fitzgerald DJ, Catella F, FitzGerald GA (1986) Platelet activation in unstable coronary disease. N Engl J Med 315:983–989

    Article  PubMed  CAS  Google Scholar 

  • Fitzgerald DJ, Fragetta J, FitzGerald GA (1988) Prostaglandin endoperoxide modulate the response to thromboxane synthase inhibition during coronary thrombosis. J Clin Invest 82:1708–1713

    Article  PubMed  CAS  Google Scholar 

  • FitzGerald GA, Brash AR, Oates JA, Pedersen AK (1983) Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 71:1336–1343

    Article  Google Scholar 

  • FitzGerald GA, Reilly IA, Pedersen AK (1985) The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 72:1194–1201

    Article  PubMed  CAS  Google Scholar 

  • FitzGerald GA (1987) Modern drug therapy: dipyridamole. N Engl J Med 316:1247–1257

    Article  PubMed  CAS  Google Scholar 

  • FitzGerald GA (1990) Ticlopidine in unstable angina. A more expensive aspirin? Circulation 82:296–298

    Article  PubMed  CAS  Google Scholar 

  • FitzGerald GA (1991) Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 68:11B–15B

    Article  PubMed  CAS  Google Scholar 

  • FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Brash AR (1993) Endogenous prostacyclin biosynthesis and platelet function during chronic aspirin administration in man. J Clin Invest 71:676–688

    Article  Google Scholar 

  • Fox JE (1993) The platelet cytoskeleton. Thromb Haemost 70:884–893

    PubMed  CAS  Google Scholar 

  • Funk CD, Funk LB, Kennedy ME, Pong AS, FitzGerald GA (1991) Human platelet/erithroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, mutagenesis and gene chromosomal assignment. Faseb J 5:2304–2312

    PubMed  CAS  Google Scholar 

  • Gawaz M, Neumann FJ, Ott I, May A, Schömig A (1996) Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 94:279–285

    PubMed  CAS  Google Scholar 

  • Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AGG, and the CATS Group (1989) The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 6:1215–1220

    Article  Google Scholar 

  • Ginsberg MH, Frelinger AL, Lam SCT, Forsyth J, McMillan R, Plow EF, Shattil SJ (1990) Analysis of platelet aggregation disorders based on flow cytometric analysis of platelet membrane glycoprotein IIb/IIIa with conformation specific monoclonal antibodies. Blood 76:2017–2023

    PubMed  CAS  Google Scholar 

  • Ginsberg MH, Du X, Plow EF (1992) Inside-out integrin signalling. Curr Opin Cell Biol 4:766–771

    Article  PubMed  CAS  Google Scholar 

  • Gogstad GO, Brosstad F, Krutnes MB, Hagen I, Solum NO (1982) Fibrinogen binding properties of the human platelet glycoprotein IIb/IIIa complex: a study using crossed-radioimmunoelectophoresis. Blood 60:663–671

    PubMed  CAS  Google Scholar 

  • Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J (1987) Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 80:1435–1445

    Article  PubMed  CAS  Google Scholar 

  • Grotta J (1993) Is aspirin effective in preventing strokes in diabetic patients? Stroke 24:760

    PubMed  CAS  Google Scholar 

  • Hall P, Nakamura S, Maiello L, Itok A, Blengino S, Martini G, Ferraro M, Colombo A (1996) A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 93:215–222

    PubMed  CAS  Google Scholar 

  • Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2294–2298

    Article  Google Scholar 

  • Harbison JW, for the Ticlopidine Aspirin Stroke Study Group (1992) Ticlopidine versus aspirin for the prevention of recurrent stroke: analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Stroke 23: 1723–1727

    Article  PubMed  CAS  Google Scholar 

  • Hla T, Neilson K (1992) Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89:7384–7388

    Article  PubMed  CAS  Google Scholar 

  • Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B, and the Ticlopidine Aspirin Stroke Study Group (1989) A randomized trial comparing ticlopidine hydrocloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321:501–507

    Article  PubMed  CAS  Google Scholar 

  • Herbert JM, Frehel D, Vallee E, Keffer G, Gouy D, Berger Y, Defreyn G, Maffrand JP (1993) Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 11:180–198

    Article  CAS  Google Scholar 

  • Hoet B, Falcon C, De Reys S, Arnout J, Deckmyn H, Vermylen J (1990) R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood 75:646–653

    PubMed  CAS  Google Scholar 

  • Keimowitz RM, Pulvermacher G, Mayo G, Fitzgerald DJ (1993) Transdermal modification of platelet function: a dermal aspirin preparation selectively inhibits paltelet cyclooxygenase and preserves prostacyclin biosynthesis. Circulation 88:556–561

    PubMed  CAS  Google Scholar 

  • Kereiakes DJ, Runyon JP, Kleiman NS et al. (1996) Differential dose-response to oral Xemilofiban after antecedent intravenous Abciximab administration for complex coronary intervention. Circulation 94:906–910

    PubMed  CAS  Google Scholar 

  • King SB, Willerson JT, Ross AM, Herrmann HC, Lipschutz KH, and the RESTORE Investigators (1996) Time course of reduction in adverse cardiac events following angioplasty using a IIb/IIIa receptor blocker, tirofiban: The restore trial. Circulation 94:1155A

    Google Scholar 

  • Kopp E, Ghosh S (1994) Inhibition of NF-kB by sodium salicylate and aspirin. Science 265:956–959

    Article  PubMed  CAS  Google Scholar 

  • Kloczewiak M, Timmons S, Lukas TJ, Hawiger J (1984) Platelet receptor recognition site on human fibrinogen: synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry 23:1767–1774

    Article  PubMed  CAS  Google Scholar 

  • Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991) TIS-10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866–12872

    PubMed  CAS  Google Scholar 

  • Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL (1994) Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271:927–934

    PubMed  CAS  Google Scholar 

  • Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chelser E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 309:396–403

    Article  PubMed  Google Scholar 

  • Maffrand JP, Defreyn G, Bernat A, Delebasse D, Tissinier AM (1988) Reviewed pharmacology of ticlopidine. Angiology 77:6–13

    Google Scholar 

  • Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ (1980) Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 66:979–986

    Article  PubMed  CAS  Google Scholar 

  • Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228–3232

    Article  PubMed  CAS  Google Scholar 

  • McAdam B, Keimowtz RM, Maher M, Fitzgerald DJ (1996) Transdermal modification of platelet function: an aspirin patch system results im marked suppression of platelet cyclooxygenase. J Pharmacol Exp Therap 277:559–564

    CAS  Google Scholar 

  • McAdam BV, FitzGerald GA (1997) Enzymatic regulation of the prostaglandin response in a human model of inflammation. In: Bazan N, Vane JR (eds) New targets in inflammation. Kluwer, Lancaster

    Google Scholar 

  • McEver RP (1990) The clinical significance of platelet membrane glycoproteins. Hematol Oncol Clin North Am 4:87–103

    PubMed  CAS  Google Scholar 

  • Mills DCB, Puri R, Hu CJ, Minniti C, Grana C, Freedman MD, Colman RF, Colman RW (1992) Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscl Thrombosis 12:430–436

    Article  CAS  Google Scholar 

  • Mitchell JA, AKarasereenont P, Thiemermann C, Flower RJ, Vane JR (1994) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693–11697

    Article  Google Scholar 

  • Muller TH, Su CA, Weisenberger H, Brickl R, Nehmiz G, Eisert WG (1990) Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 30:179–186

    PubMed  CAS  Google Scholar 

  • Muller TH, Weisenberger H, Brickl R, Kirchner M, Narjes H, Himmelsbach F, Guth B, Krause J (1995) Pharmaco-dynamics and kinetics of BIBU 52, a platelet glycoprotein (GP) IIb/IIIa antagonist and its orally active prodrug BIBU 104 in man. Thromb Haem 73:2081A

    Google Scholar 

  • Nichols AJ, Ruffolo RR, Huffman WF, Poste G, Samanen J (1992) Development of Gp IIb/IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci 13:413–417

    Article  PubMed  CAS  Google Scholar 

  • Nowak J, FitzGerald GA (1989) Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest 83:380–385

    Article  PubMed  CAS  Google Scholar 

  • Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ, for the IMPACT-AMI Investigators (1997) Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation (in press)

    Google Scholar 

  • Paragon Investigators (1996) A randomized trial of potent platelet IIb/IIIa antagonism, heparin or both in patients with unstable angina. The PARAGON study. Circulation 94:3234A

    Google Scholar 

  • Parise LV, Phillips DR (1985) Reconstitution of the purified platelet fibrinogen receptor: fibrinogen binding properties of the glycoprotein IIb/IIIa complex. J Biol Chem 260:10698–10707

    PubMed  CAS  Google Scholar 

  • Parise LV, Helgerson SL, Steiner B, Nannizzi L, Phillips DR (1987) Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet glycoprotein IIb/IIIa. J Biol Chem 262:12597–12602

    PubMed  CAS  Google Scholar 

  • Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366–1372

    Article  PubMed  CAS  Google Scholar 

  • Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Creminon C, Maclouf J, Patrono C (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exper Therap 271:1705–1712

    CAS  Google Scholar 

  • Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311:1206–1211

    Article  PubMed  CAS  Google Scholar 

  • Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R (1988) Randomised trial of prophy lactic daily aspirin in British male doctors. Brit Med 296:313–316

    Article  CAS  Google Scholar 

  • Phillips DR, Charo IF, Scarborough RM (1991) Gp IIb/IIIa: the responsive integrin. Cell 65:359–362

    Article  PubMed  CAS  Google Scholar 

  • Plow EF, Ginsberg MH (1989) GpIIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 9:117–156

    PubMed  CAS  Google Scholar 

  • Resar JR, Brinker JA, Gerstenblith G, Blumenthal RS, Dudek A, Coombs VJ, Goldschmidt-Clermont PJ (1996) Disparity of Integrilin inhibition of platelet aggregation and GP IIb/IIIa fibrinogen binding in angioplasty patients. Circulation 94:567A

    Google Scholar 

  • Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB (1994) Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arteriosclerosis Thrombosis 14:1021–1031

    Article  CAS  Google Scholar 

  • Roth GJ, Majerus PW (1975) The mechanism of the effect of aspirin on platelets. Acetylation of a particular fraction protein. J Clin Invest 56:624–632

    Article  PubMed  CAS  Google Scholar 

  • Roth GJ, Stanford N, Majerus PW (1975) Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 72:3073–3076

    Article  PubMed  CAS  Google Scholar 

  • Ruoshlati E, Pierschbacher MD (1986) Arg-Gly-Asp: a versatile cell recognition signal. Cell 44:517–518

    Article  Google Scholar 

  • Savage MP, Goldberg S, Bove A et al., for the M-HEART II Study Group (1995) Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 92:3194–3200

    PubMed  CAS  Google Scholar 

  • Savi P, Laplace MC, Maffrand JP, Herbert JM (1994) Binding of 3H-2-Methylthio ADP to rat platelets. Effect of Clopidogrel and ticlopidine. J Pharmacol Exp Ther 269:772–777

    PubMed  CAS  Google Scholar 

  • Scarborough RM, Rose JW, Hsu MA et al. (1991) Barbourin: a GpIIb/IIIa-specific integrin antagonist from the venom of Sisturus m. barbouri. J Biol Chem 266:9359–9362

    PubMed  CAS  Google Scholar 

  • Schafer AI, Crawford DD, Gimbrone MA (1984) Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J Clin Invest 73:1105–1112

    Article  PubMed  CAS  Google Scholar 

  • Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR (1988) Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 318:1714–1719

    Article  PubMed  CAS  Google Scholar 

  • Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stibbe J, for the CARPORT Study Group (1991) Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Circulation 84:1568–1580

    PubMed  CAS  Google Scholar 

  • Shattil SJ, Hoxie JA, Cunningham M, Brass LF (1985) Changes in the platelet membrane glycoprotein IIb/IIIa comples during platelet activation. J Biol Chem 260:11107–11114

    PubMed  CAS  Google Scholar 

  • Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, Kass R, Blanche C, Matloff J, Morgenstern et al. (1986) Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 315:913–919

    Article  PubMed  CAS  Google Scholar 

  • Simoons ML, de Boer JM, van den Brand MJBM, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF et al. (1994) Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 89:596–603

    PubMed  CAS  Google Scholar 

  • Simpfenndorfer C, Kottke-Marchant Kandice, Topol E (1996) First experience with chronic platelet Gp IIb/IIIa receptor blockade: A pilot study of xemilofiban, an orally active antagonist, in unstable angina patients eligible for PTCA. J Am Coll Cardiol 27:242A

    Google Scholar 

  • Smith WL (1992) Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263:F181–F191

    PubMed  CAS  Google Scholar 

  • Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 321:129–135

    Article  Google Scholar 

  • Tcheng JE, Harrington RA, Kottke-Marchant K et al. (1995a) Multicenter randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 91:2151–2157

    PubMed  CAS  Google Scholar 

  • Tcheng JE, Lincoff M, Sigmon KN et al. (1995b) Platelet glycoprotein IIb/IIIa inhibition with Integrelin during percutaneous coronary intervention: The IMPACT II Trial. Circulation 92:2595A

    Google Scholar 

  • Tcheng JE (1996) Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE and EPILOG trials into perspective. Am J Cardiol 78:35–40

    Article  PubMed  CAS  Google Scholar 

  • The EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956–961

    Article  Google Scholar 

  • The RAPT Investigators (1994) Randomized trial of Ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel versus aspirin patency trial (RAPT). Circulation 89:588–595

    Google Scholar 

  • Théroux P, Latour JG, Leger-Gauthier C, De Lara J (1987) Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 75:156–162

    Article  PubMed  Google Scholar 

  • Théroux P, Kouz S, Roy L et al., on behalf of the Investigators (1996) Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 94:899–905

    PubMed  Google Scholar 

  • Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, The EPIC Investigators (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343:881–886

    Article  PubMed  CAS  Google Scholar 

  • Van de Werf F (1996) More evidence for a beneficial effect of platelet glycoprotein IIb/ IIIa blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. Eur Heart J 17:325–326

    PubMed  Google Scholar 

  • Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231:232–235

    CAS  Google Scholar 

  • van Gijn J, Algra A (1994) Ticlopidine: trials and torture. Stroke 25:1097–1098

    Article  PubMed  Google Scholar 

  • Weber C, Erl W, Pietsch A, Weber PC (1995) Aspirin inhibits nuclear factor-kB mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 91:1914–1917

    PubMed  CAS  Google Scholar 

  • Weisberg LA (1993) The efficacy and safety of ticlopidin and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. Neurology 43:27–31

    PubMed  CAS  Google Scholar 

  • Weiss E, Bray PF, Tayback M, Schulman SP, Kickler TS, Becher LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ (1996) A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334:1090–1094

    Article  PubMed  CAS  Google Scholar 

  • Yao SK, Ober JC, Ferguson JJ, Andersson HV, Maraganore J, Buja LM, Willerson JT (1992a) Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation 86:1993–1999

    PubMed  CAS  Google Scholar 

  • Yao SK, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand JP, Campbell WB, Buja LM, Willerson JT (1992b) ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 70:39–48

    PubMed  CAS  Google Scholar 

  • Yao SK, Ober JC, Ferguson JJ, Maffreand JP, Anderson HV, Buja LM, Willerson JT (1994) Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 267:H488–H493

    PubMed  CAS  Google Scholar 

  • Yokoyama C, Tanabe T (1989) Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Comm 165:888–894

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. F. Catella-Lawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. A. FitzGerald
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Pharmakologie, Freie Universität Berlin, Thielallee 69-73, 14195, Berlin, Germany

    Franz von Bruchhausen

  2. Institut für Klinische Biochemie und Pathobiochemie, Medinzinische Universitätsklinik, Josef-Schneider-Str. 2, 97080, Würzburg, Germany

    Ulrich Walter

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Catella-Lawson, F., FitzGerald, G.A. (1997). Therapeutic Aspects of Platelet Pharmacology. In: von Bruchhausen, F., Walter, U. (eds) Platelets and Their Factors. Handbook of Experimental Pharmacology, vol 126. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60639-7_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60639-7_29

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64488-7

  • Online ISBN: 978-3-642-60639-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation